First Clinical Trial Begins for RNA-based Therapy SPL84 for CF
SpliSense has launched a Phase 1/2 clinical trial to test SPL84, its inhaled treatment candidate for cystic fibrosis (CF) patients carrying a common disease-causing splicing mutation. As of now, no specific treatment is available for people with CF who carry this particular mutation. Called 3849+10 kb C-to-T, it…